Enlicitide is an oral prescription medication for lowering cholesterol. Its strongest evidence concerns cholesterol reduction when existing treatment leaves cholesterol high. Enlicitide-specific prevention of cardiovascular events and lifespan extension remain unproven. Evidence comes mainly from one manufacturer-sponsored program. Daily administration and food timing matter; diarrhea and dizziness are possible burdens, pregnancy raises a theoretical concern, and rare or delayed harms remain poorly characterized. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | No established target for enlicitide longevity use; track baseline change and individualized clinical goals | Expected treatment response |
| Apolipoprotein B | No established target for enlicitide longevity use; track change from baseline | Expected particle-burden response |
| Non-HDL cholesterol | No established target for enlicitide longevity use; track change from baseline | Expected lipid response |
| Lipoprotein(a) | No established enlicitide target; track baseline and change if elevated | Expected secondary marker response |
| Triglycerides | Not specified in the ER | Context for fasting sampling |
Cadence: Baseline; practical, nonvalidated lipid follow-up at 4–8 weeks, after material regimen changes, then every 3–6 months once stable. Symptoms during the first month and at each review.